Literature DB >> 12423981

Effect of radiotherapy and other treatment-related factors on mid-term to long-term cognitive sequelae in low-grade gliomas: a comparative study.

M Klein1, J J Heimans, N K Aaronson, H M van der Ploeg, J Grit, M Muller, T J Postma, J J Mooij, R H Boerman, G N Beute, G J Ossenkoppele, G W van Imhoff, A W Dekker, J Jolles, B J Slotman, H Struikmans, M J B Taphoorn.   

Abstract

BACKGROUND: Because survival benefits of treatment with radiotherapy are questionable and such treatment can cause substantial damage to the brain over time, the optimum management strategy for low-grade gliomas remains controversial. We aimed to identify the specific effects of radiotherapy on objective and self-reported cognitive function, and on cognitive deterioration over time, in patients with low-grade gliomas treated with early radiotherapy.
METHODS: 195 patients with low-grade glioma (of whom 104 had received radiotherapy 1-22 years previously) were compared with 100 low-grade haematological patients and 195 healthy controls. Our analyses aimed to differentiate between the effects of the tumour (eg, disease duration, lateralisation) and treatment effects (neurosurgery, radiotherapy, antiepileptic drugs) on cognitive function and on relative risk of cognitive disability.
FINDINGS: Low-grade glioma patients had lower ability in all cognitive domains than did low-grade haematological patients, and did even less well by comparison with healthy controls. Use of radiotherapy was associated with poorer cognitive function; however, cognitive disability in the memory domain was found only in radiotherapy patients who received fraction doses exceeding 2 Gy. Antiepileptic drug use was strongly associated with disability in attentional and executive function.
INTERPRETATION: Our findings suggest that the tumour itself has the most deleterious effect on cognitive function and that radiotherapy mainly results in additional long-term cognitive disability when high fraction doses are used. Additionally, the effects of other medical factors, especially antiepileptic drug use, on cognitive function in glioma patients deserve attention.

Entities:  

Mesh:

Year:  2002        PMID: 12423981     DOI: 10.1016/s0140-6736(02)11398-5

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  162 in total

1.  White matter compromise predicts poor intellectual outcome in survivors of pediatric low-grade glioma.

Authors:  Fang Liu; Nadia Scantlebury; Uri Tabori; Eric Bouffet; Suzanne Laughlin; Douglas Strother; Dina McConnell; Juliette Hukin; Chris Fryer; Marie-Eve Brière; Isabelle Montour-Proulx; Daniel Keene; Frank Wang; Donald J Mabbott
Journal:  Neuro Oncol       Date:  2014-11-13       Impact factor: 12.300

2.  The dilemma of low grade glioma.

Authors:  I R Whittle
Journal:  J Neurol Neurosurg Psychiatry       Date:  2004-06       Impact factor: 10.154

Review 3.  [Neurological complications of neurooncological therapy].

Authors:  U Herrlinger; J P Steinbach
Journal:  Nervenarzt       Date:  2010-08       Impact factor: 1.214

Review 4.  Review on quality of life issues in patients with primary brain tumors.

Authors:  Martin J B Taphoorn; Eefje M Sizoo; Andrew Bottomley
Journal:  Oncologist       Date:  2010-05-27

Review 5.  Psychosocial distress and its effects on the health-related quality of life of primary brain tumor patients.

Authors:  Dina Randazzo; Katherine B Peters
Journal:  CNS Oncol       Date:  2016-07-11

6.  Pitfalls in the assessment of disability in individuals with low-grade gliomas.

Authors:  Anneli Påhlson; Lena Ek; Gerd Ahlström; Anja Smits
Journal:  J Neurooncol       Date:  2003-11       Impact factor: 4.130

Review 7.  Neurocognitive functioning in adult WHO grade II gliomas: impact of old and new treatment modalities.

Authors:  Martin Klein
Journal:  Neuro Oncol       Date:  2012-09       Impact factor: 12.300

Review 8.  Factors influencing quality of life in adult patients with primary brain tumors.

Authors:  Rakesh Jalali; Debnarayan Dutta
Journal:  Neuro Oncol       Date:  2012-09       Impact factor: 12.300

9.  Risk for unemployment at 10 years following cancer diagnosis among very long-term survivors: a population based study.

Authors:  Yakir Rottenberg; Angela G E M de Boer
Journal:  J Cancer Surviv       Date:  2020-02-14       Impact factor: 4.442

10.  Chemotherapy for adult low-grade gliomas: clinical outcomes by molecular subtype in a phase II study of adjuvant temozolomide.

Authors:  Michael Wahl; Joanna J Phillips; Annette M Molinaro; Yi Lin; Arie Perry; Daphne A Haas-Kogan; Joseph F Costello; Manisha Dayal; Nicholas Butowski; Jennifer L Clarke; Michael Prados; Sarah Nelson; Mitchel S Berger; Susan M Chang
Journal:  Neuro Oncol       Date:  2017-02-01       Impact factor: 12.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.